Absci Corporation (NASDAQ: ABSI) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Absci Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $7.58, Absci Corporation trades at 871.9x sales and 5.9x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $138M. It runs a gross margin of -2647.4%, an operating margin of -9155.3% and a net margin of -8451.3%. It shows return on equity of -60.8%, return on invested capital of -61.0% and a free cash flow yield of -8.6%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 9.64. Over the past 52 weeks the share price ranged from $2.24 to $12.54, with a beta of 2.23.
Absci Corporation does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.